Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 31Expanded_access 2Observational 1

Sponsor

Cancer Type

CNS 11Dermatologic 2Sarcoma 1Gastrointestinal 1

Conditions

Melanoma 21Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinoma, Basal Cell 3Uveal Melanoma 2Prostatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Glioma 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Keratosis 1Hodgkin Disease 1Hematologic Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory 1Cholangiocarcinoma 1

Interventions

pembrolizumab 1efineptakin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Glioma × Dermatologic × Clear all
NCT04289155 2022-03-17

Individual Patient Compassionate Use of GX-I7

Genexine, Inc.

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

NCT03311542 2018-01-10

Expanded Access for Pembrolizumab (MK-3475)

Center Trials & Treatment

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡